Abstract
Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Keywords: Plaque, atherothrombosis, COX-2
Current Vascular Pharmacology
Title: Genetic and Molecular Determinants of Atherosclerotic Plaque Instability
Volume: 8 Issue: 4
Author(s): Francesco Cipollone, Elena Toniato, Stefano Martinotti and Andrea Mezzetti
Affiliation:
Keywords: Plaque, atherothrombosis, COX-2
Abstract: Arachidonic acid metabolism plays a key role in atherothrombotic events affecting the coronary or cerebrovascular territory, as reflected by experimental studies based on biochemical measurements of eicosanoid biosynthesis and the results of inhibitor trials in these settings. Two cyclooxygenase (COX)-isozymes exist, COX-1 and COX-2, that differ in terms of regulatory mechanisms of expression, tissue distribution, substrate specificity, and susceptibility to inhibition by drugs. Whereas the role of COX-1 expressed in platelets in acute coronary syndromes and ischemic stroke is definitely established through several large clinical studies with aspirin, the role of COX-2 activity in these settings is still unclear, because this enzyme was characterized only recently (1991) and its inhibitors (coxibs) only became available in 1998. In this review, we discuss the different expression profile of COX-2-related enzymes in the cells actively involved in atherothrombosis, the role of these enzymes as cause of plaque “instability”, and the clinical consequences of their inhibition. Recent studies suggest that variable expression of transmembrane and downstream receptors, as well as genetic mutations represent important determinants of the functional consequences of COX-2 expression and inhibition in different clinical settings.
Export Options
About this article
Cite this article as:
Cipollone Francesco, Toniato Elena, Martinotti Stefano and Mezzetti Andrea, Genetic and Molecular Determinants of Atherosclerotic Plaque Instability, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330825
DOI https://dx.doi.org/10.2174/157016110791330825 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Adjunctive Therapies in Severe Pneumonia in Critical Care Patients
Infectious Disorders - Drug Targets Phytoestrogens and other Botanicals: On the Problems of Evidence-based Evaluation
Recent Patents on Cardiovascular Drug Discovery Omega-3 Fatty Acids: Role in Metabolism and Cardiovascular Disease
Current Pharmaceutical Design Cardiovascular Disease Risk and Hormone Replacement Therapy (HRT): A Review Based on Randomised, Controlled Studies in Postmenopausal Women
Current Medicinal Chemistry Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews The Proteomic Approach in the Development of Prognostic Biomarkers in Atherothrombosis
Recent Patents on Cardiovascular Drug Discovery Enhancing Central Nervous System Endogenous GLP-1 Receptor Pathways for Intervention in Alzheimers Disease
Current Alzheimer Research Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Endothelial Progenitors in Vascular Repair and Angiogenesis: How Many are Needed and What to do?
Cardiovascular & Hematological Disorders-Drug Targets Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology A Timely Review of State-of-the-Art Chronopharmaceuticals Synchronized with Biological Rhythms
Current Drug Delivery Effect of Long Chain n-3 PUFA on Endothelial Activation, Endothelial Function and Atheromatous Plaque Stability
Current Nutrition & Food Science The L-Type Ca2+ Channel as a Therapeutic Target in Heart Disease
Current Medicinal Chemistry Oleacein. Translation from Mediterranean Diet to Potential Antiatherosclerotic Drug
Current Pharmaceutical Design Editorial (Thematic Issue: Cardiovascular Drug Therapy in Paediatric Age: From Metabolomics to Clinical Practice)
Current Medicinal Chemistry Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Cardiovascular & Hematological Agents in Medicinal Chemistry Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets